The Drug Controller General of India (DCGI) has granted clearance to Takeda's QDENGA, marking the first approved dengue vaccine in India [1].
This approval provides a critical new tool for public health officials in a country where dengue is a rapidly growing mosquito-borne disease [2]. The vaccine is intended to reduce the burden of illness and hospitalization associated with the virus.
QDENGA is approved for use in individuals between the ages of four and 60 [2]. Unlike some previous iterations of dengue prevention, this vaccine is designed to provide protection across all four dengue virus serotypes [2]. This broad coverage is essential because infection with one serotype does not provide immunity against the others.
Medical providers said that the vaccine does not require prior infection testing [2]. This removes a significant clinical barrier, as patients do not need to prove they have previously had dengue before receiving the shot.
The DCGI's decision comes as India continues to face seasonal surges of the virus. By targeting a wide age demographic and covering all four strains, the vaccine aims to lower the overall incidence of severe dengue cases across the population [2].
Public health officials said there is a need for such interventions as urban expansion and changing weather patterns increase the prevalence of the Aedes mosquito. The introduction of QDENGA represents a shift toward preventative immunization in a region that has historically relied on vector control and supportive care [3].
“India approved its first dengue vaccine, Takeda's QDENGA.”
The approval of QDENGA in India shifts the national strategy against dengue from reactive treatment and mosquito control to proactive prevention. Because the vaccine covers all four serotypes and does not require pre-screening for prior infections, it is positioned for large-scale deployment, potentially reducing the seasonal strain on the Indian healthcare system.
